Tibet Duo Rui Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of chemical preparations, intermediates and active pharmaceutical ingredients. The Company mainly has self-produced products such as Sodium Acetate Ringer Injection and agent products such as Amoxicillin Sodium and Clavulanate Potassium for Injection. The Company's products mainly include liquid therapy, emergency medication, pediatric medication, psychiatric medication, and analgesic medication. The Company mainly operates its businesses in the domestic market.

Employees

461

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
30/10/26	CN¥45.55	-5.46%	1,166,917
29/10/26	CN¥48.18	-5.62%	906,900
28/10/26	CN¥51.05	+5.26%	959,978
27/10/26	CN¥48.50	-6.01%	1,001,900
26/10/26	CN¥51.60	-3.80%	821,200

End-of-day quote Shenzhen S.E.

More quotes

End-of-day quote Shenzhen S.E. 30/10/2026			5-day change	1st Jan Change
45.55 ^CNY	-5.46%		-15.08%	-23.66%

10-28	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2026	CI
09-29	Certain A Shares of Tibet Duo Rui Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 29-SEP-2026.	CI

Market Cap	3.64B 547M 490M 451M 409M 764M 51.98B 778M 5.38B 2.16B 27.35B 2.05B 2.01B 86.24B	P/E 2024	-22.7x	P/E 2025	-46.3x
Enterprise Value	3.97B 597M 534M 491M 445M 832M 56.65B 848M 5.86B 2.35B 29.8B 2.24B 2.19B 93.97B	EV / Sales 2024	6.46x	EV / Sales 2025	32.7x
Free-Float	32.51%	Yield 2024 *	-	Yield 2025	-

10-28	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2026	CI
09-29	Certain A Shares of Tibet Duo Rui Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 29-SEP-2026.	CI
09-20	Tibet Duo Rui Pharmaceutical Co., Ltd.(XSEC:301075) added to S&P Global BMI Index	CI
08-25	Tibet Jiakang TImes Technology Development Co., Ltd. agreed to acquire Hubei Duorui Pharmaceutical Co., Ltd. from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 77.3 million.	CI
08-25	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
04-28	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-23	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-22	Tibet Jiakang TImes Technology Development Co., Ltd. agreed to acquire Hubei Hairuidi Pharmaceutical Co., Ltd from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 2.4 million.	CI
04-22	Tibet Jiakang TImes Technology Development Co., Ltd. entered into an Equity Transfer Agreement to acquire 69% stake in Xiamen Ruitilian Pharmaceutical Technology Co., Ltd. from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 27.6 million.	CI
04-22	Tibet Jiakang TImes Technology Development Co., Ltd. agreed to acquire Wuhan Duorui Industrial Co., Ltd from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 5.1 million.	CI
02-26	Wang Qingtai and Cao Xiaobing completed the acquisition of an additional 24.30% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Tibet Jiakang TImes Technology Development Co., Ltd.	CI
02-24	Trading in Tibet Duo Rui Pharmaceutical's shares to halt	RE
01-20	Wang Qingtai and Cao Xiaobing proposed to acquire additional 24.30% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Tibet Jiakang TImes Technology Development Co., Ltd. for approximately CNY 620 million.	CI

1 day	-5.46%
1 week	-15.08%
1 month	-27.89%
3 months	-8.57%
6 months	-45.42%
Current year	-23.66%

Tibet Duo Rui Pharmaceutical Co., Ltd. Share Price

Stocks

301075

CNE100004RW5

Pharmaceuticals

Valuation: Tibet Duo Rui Pharmaceutical Co., Ltd.

Chart: Tibet Duo Rui Pharmaceutical Co., Ltd.

Latest news: Tibet Duo Rui Pharmaceutical Co., Ltd.

Quotes and Performance

Price Extremes

Managers and Directors: Tibet Duo Rui Pharmaceutical Co., Ltd.

Other Pharmaceuticals

Financials

Company Profile

Quotes

1 week	45.4	53.7
1 month	45.4	64
Current year	44.55	98.29
1 year	44.55	98.29
3 years	12.6	98.29
5 years	12.6	98.29
10 years	12.6	98.29

Manager	Title	Age	Since
Yong Deng CEO	Chief Executive Officer	60	30/11/2018
Chao Li DFI	Director of Finance/CFO	47	30/04/2017
Fen Jin DFI	Director of Finance/CFO	46	30/11/2017

Director	Title	Age	Since
Yong Deng CHM	Chairman	60	30/11/2017
Shao Zhong Zhang BRD	Director/Board Member	70	20/02/2020
Qin Deng BRD	Director/Board Member	58	20/02/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TIBET DUO RUI PHARMACEUTICAL CO., LTD.	-5.46%	-15.08%	-18.91%	+56.74%	547M
ELI LILLY AND COMPANY	+3.19%	+11.31%	+64.28%	+155.91%	1,263B
JOHNSON & JOHNSON	-0.73%	+3.56%	+44.65%	+84.17%	658B
ABBVIE INC.	+1.41%	+3.24%	+35.25%	+108.88%	521B
ROCHE HOLDING AG	+0.42%	+3.20%	+55.81%	+72.50%	391B
MERCK & CO., INC.	+2.18%	+2.93%	+73.90%	+45.59%	369B
NOVARTIS AG	+1.12%	+4.52%	+34.76%	+58.24%	307B
ASTRAZENECA PLC	+6.96%	+8.86%	+11.95%	+36.20%	290B
AMGEN INC.	+1.15%	+6.09%	+56.15%	+82.25%	252B
GILEAD SCIENCES, INC.	+3.06%	+9.38%	+42.48%	+117.32%	212B
Average	+1.33%	+4.14%	+40.03%	+81.78%	426.25B
Weighted average by Cap.	+2.01%	+6.60%	+50.50%	+100.43%

	2024	2025
Net sales	241M 36.15M 32.38M 29.78M 26.99M 50.44M 3.43B 51.39M 355M 143M 1.81B 136M 133M 5.69B	154M 23.16M 20.75M 19.08M 17.29M 32.32M 2.2B 32.93M 228M 91.35M 1.16B 86.93M 85.08M 3.65B
Net income	-62.67M -9.42M -8.43M -7.76M -7.03M -13.14M -894M -13.38M -92.5M -37.13M -470M -35.33M -34.58M -1.48B	-102M -15.35M -13.75M -12.65M -11.46M -21.42M -1.46B -21.82M -151M -60.54M -767M -57.61M -56.38M -2.42B
Net Debt	135M 20.24M 18.12M 16.67M 15.1M 28.23M 1.92B 28.76M 199M 79.8M 1.01B 75.94M 74.33M 3.19B	327M 49.09M 43.97M 40.44M 36.64M 68.5M 4.66B 69.78M 482M 194M 2.45B 184M 180M 7.73B